Biotechnology

Nucleome Therapeutics Bolsters Leadership with Appointment of Dr. Michelle Morrow as Chief Scientific Officer

by
Dr. Michelle Morrow, newly appointed Chief Scientific Officer of Nucleome Therapeutics, an experienced biotech executive in immunology and drug development.

“Nucleome Therapeutics, a pioneering UK-based biotech firm focused on decoding non-coding human genetics to address inflammatory diseases, has named Dr. Michelle Morrow as its new Chief Scientific Officer, effective February 23, 2026. With over two decades of experience in drug discovery, development, and R&D strategy across biotech and pharmaceutical sectors, Dr. Morrow brings proven expertise … Read more

Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results

by
BridgeBio Pharma stock chart showing upward trend

BridgeBio Pharma showcased impressive revenue growth throughout 2025, fueled by surging sales of its flagship ATTR-CM treatment Attruby, alongside strategic financial maneuvers that bolstered its cash position and supported pipeline advancements, prompting widespread analyst optimism with consensus buy ratings and elevated price targets averaging around $85, reflecting confidence in sustained momentum and multi-product potential. BridgeBio … Read more